Cite

HARVARD Citation

    Jonczak, S. et al. (2022). Inflammatory Myofibroblastic Tumor Refractory to Three Lines of ALK Inhibitors and Combination Immunotherapy. International journal of clinical and medical cases. 5 (2), p. . [Online]. 
  
Back to record